1 Reason to Buy Novavax Stock, and 3 (Better) Reasons to Sell
Like many of the biotechs pursuing coronavirus vaccine development, (NASDAQ: NVAX) has seen better days. Its shares are down by 96% over the past three years, and the company's remaining shareholders face fading hopes for a spontaneous revival.
Nonetheless, while there are a few good arguments for why you should avoid investing, there's still one big reason to buy Novavax stock. Let's discuss the major point in its favor that might drive some to be interested in buying it, then follow up with a trio of reasons it would probably be better to sell.
As a vaccine business, Novavax intended its coronavirus vaccine, Nuvaxovid, to be its first commercialized product as well as its golden goose. Now, with trailing-12-month revenue of just over $1 billion -- down from nearly $2 billion in 2022 -- many would say that Nuvaxovid was not nearly as much of a success as the ubiquitous shots made by Pfizer and Moderna.
Source Fool.com
Novavax Inc. Stock
With 7 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 26 € shows a very positive potential of 82.02% compared to the current price of 14.28 € for Novavax Inc..
